35 results about "Dosing Frequency" patented technology

The present invention belongs to the field of biopharmaceuticals, and particularly relates to a multi-domain active protein for treating metabolic diseases. The multi-domain active protein has a structural formula as shown in Formula I: A-L a -F-L b -B. Compared with the prior art, the multi-domain active protein of the present invention has a long half-life and supports a once-weekly dosing frequency; the GLP-1R agonist activity of the multi-domain active protein is increased by more than 200 times at most; the multi-domain active protein has good stability in vivo and in vitro and low immunogenicity; since no unnatural amino acids need to be introduced and no chemical synthesis and cross-linking steps are involved, it can be prepared by a recombinant method, greatly simplifying the preparation process.

The invention discloses an application and a preparation of a miR-125b-5p inhibitor or antagonist for treating and / or preventing myopia. According to the application, a miR-125b-5p inhibitor or antagonist, particularly miR-125b-5p antiagomir with a nucleotide sequence as shown in SEQ ID NO: 8, is used for inhibiting the expression of miR-125b-5p in sclera and increasing the expression of a target gene tp53, so that the transdifferentiation of sclera fibroblasts can be remarkably reduced, sclera remodeling can be reduced, and the diopter reduction and ocular axis extension of guinea pig deprivation myopia can be retarded; the composition can be used for preventing myopia and controlling myopia progress, has the advantages of low administration frequency and high safety, and provides a safer, more effective and more convenient prevention and control means for myopia patients, especially teenagers.

The present invention relates to therapeutic compositions and methods for the treatment of attention deficit disorder (ADD), or attention deficit hyperactivity disorder (ADHD). The present invention more particularly relates to a modified-release pharmaceutical formulation designed to improve the delivery and efficacy of central nervous system (CNS) stimulants. The composition consists of a drug-containing core with a CNS stimulant and pharmaceutically acceptable excipients. This core is coated with a sustained-release (SR) layer comprising one or more polymers selected from water-insoluble and water-insoluble pH-dependent polymers, and one or more pharmaceutically acceptable excipients which regulates the gradual release of the drug. Surrounding the SR layer is a delayed-release (DR) outer layer that controls the onset of drug release. This approach aims to enhance symptom control, reduce dosing frequency, and improve patient compliance in the treatment of ADD and ADHD.

This invention describes a novel, stable, fixed-dose, aqueous suspension of Amoxicillin Clavulanate for nasal administration to treat post-surgical nasal infections. The formulation leverages a unique combination of excipients, including mucoadhesive agents like chitosan, to enhance drug delivery and efficacy. Key features include targeted delivery to the infection site, sustained release for reduced dosing frequency, and the ability to disrupt bacterial biofilms. This innovative approach addresses the limitations of current treatment options by providing effective local drug delivery, minimizing systemic side effects, and improving patient compliance.

The present invention provides an antibody or antigen-binding portion thereof that can bind to properdin (factor P). The antibody of the current invention leads to selective inhibition of alternative complement pathway while allowing the classical and lectin pathways to continue. Further, the antibody of the present invention may have modified or reduced binding to FcγRs to minimize its ADCC activity. The present invention provide an antibody that comprises an amino acid sequence to minimise its CDC activity. The antibody according to the present invention has higher FcRn binding affinity and therefore the antibody according to the present invention may have long circulating half-life in the body of the patient and it can be given at a reduced dosing frequency. The antibody according to the present invention can further be used in the preparation of a drug for treating diseases through inhibition of alternative complement pathway.

An external or topical formulation for treatment or prevention of infections involving body surfaces using a depsipeptide antibiotic drug such as lotilibcin having improved efficacy and safety is provided. The antibacterial effect of lotilibcin tested in infectious models is substantially enhanced by addition of boric acid in a low concentration of an additive level which does not produce any pharmacological activity by itself, thereby offering a formulation for external preparations having improved safety due to a decrease in dose, dosing period, and dosing frequency.

The disclosure provides improved human FGF23-binding antibodies with increased affinity for human FGF23 as compared to burosumab, enabling reduced dosing frequency, improving convenience of therapy, and achieving higher efficacy compared to burosumab, without compromising safety.

The present invention relates to therapeutic compositions and methods for the treatment of attention deficit disorder (ADD), or attention deficit hyperactivity disorder (ADHD). The present invention more particularly relates to a modified-release pharmaceutical formulation designed to improve the delivery and efficacy of central nervous system (CNS) stimulants. The composition consists of a drug-containing core with a CNS stimulant and pharmaceutically acceptable excipients. This core is coated with a sustained-release (SR) layer comprising one or more polymers selected from water-insoluble and water-insoluble pH-dependent polymers, and one or more pharmaceutically acceptable excipients which regulates the gradual release of the drug. Surrounding the SR layer is a delayed-release (DR) outer layer that controls the onset of drug release. This approach aims to enhance symptom control, reduce dosing frequency, and improve patient compliance in the treatment of ADD and ADHD.

This invention relates to wastewater treatment control technology, and discloses an intelligent carbon source dosing system and method for wastewater treatment with load sensing and allocation functions. The method includes: carbon source dosing, which involves adding carbon source to the anoxic tank and denitrification tank via a carbon source dosing pump unit; controlling the carbon source dosing frequency, which involves controlling the carbon source dosing frequency of the carbon source dosing pump unit via a carbon source dosing pump control cabinet; and feeding back the carbon source dosing amount to the carbon source dosing pump control cabinet; and determining the carbon source dosing amount, which is controlled by the intelligent carbon source dosing system through controlling the frequency of the carbon source dosing pump unit. The control of the carbon source dosing amount is achieved by controlling the carbon source dosing pump unit through the intelligent carbon source dosing system. This invention can detect the carbon source dosing amount in real time, and it offers good safety, low cost, and simple operation.

An autoserum eye drop administration device comprises a bottle body, a bottom cover and a bottle mouth, an arc-shaped tunnel is arranged in the bottle body, the upper end of the arc-shaped tunnel extends to the bottle mouth, the lower end of the arc-shaped tunnel extends to the bottom cover, a liquid medicine capsule is contained in the arc-shaped tunnel, a separation opening is formed in the side wall of the arc-shaped tunnel, one end of an elastic button is exposed out of the bottle body, and the other end of the elastic button extends to the separation opening. Extruding the liquid medicine capsule; the bottle neck is in threaded connection with the bottle body, a fine needle is arranged in the bottle neck, a fine needle reserved opening is formed in the upper portion of the arc-shaped tunnel, and the bottle neck is rotated to enable the fine needle to enter the arc-shaped tunnel from the fine needle reserved opening and pierce the liquid medicine capsule. By means of the structure, the autoserum eye drop dosing device can be matched with a liquid medicine capsule to conduct autoserum eye drop dosing, pollution is not prone to occurring, the dosing frequency can be increased, and waste is not prone to being caused.

The present invention relates to an injectable formulation, a method for treating a metabolic disease and an administration device. The injectable formulation comprises a lipid matrix composition, a specific amount of a GLP-1 receptor agonist and at least one pharmaceutically acceptable ion. Accordingly, upon contacting an aqueous fluid, the injectable formulation forms a depot exhibiting an extended release of the GLP-1 receptor agonist in vivo or in vitro. In the method for treating the metabolic disease, the injectable formulation can be administered to a subject with a reduced dosing frequency, and it is not necessary to store the injectable formulation for the next administration. For the administration device, the injectable formulation is filled in a vial, a pre-filled syringe or a pre-filled cartridge. Therefore, the injectable formulation can be designed for a single use, thereby enhancing convenience, compliance and adherence of a subject.

The utility model belongs to the technical field of sewage treatment, and particularly relates to a dosing device for rural sewage treatment, which comprises a barrel, a top cover is screwed at the top end of the barrel in a threaded manner, a water inlet pipe is fixedly mounted on the top cover, a bottom cover is screwed at the bottom of the barrel in a threaded manner, and a bent pipe is fixedly communicated with the barrel. A bent pipe is fixedly communicated with a through pipe, a height adjusting pipe is arranged at the top of the through pipe in a sliding and penetrating mode, a water outlet pipe is installed on the height adjusting pipe, and a locking assembly is installed between the through pipe and the height adjusting pipe. And the manual dosing frequency of personnel is effectively reduced.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a sustained-release analgesic pharmaceutical composition as well as a preparation method and application thereof. The pharmaceutical composition comprises a drug, a delivery carrier and a release regulator, the medicine is selected from at least one of local anesthetics and non-steroidal anti-inflammatory drugs; the release regulator is selected from phospholipid compounds; the delivery carrier is selected from saccharides and esters thereof. According to the invention, the phospholipid compound is adopted as the release regulator, and the phospholipid compound and the delivery carrier act together to increase the initial release blood concentration of the drug in vivo, shorten the peak time of the blood concentration, enhance the analgesic drug effect at the initial stage of the operation, maintain the long-acting release of the drug, effectively relieve the postoperative pain, reduce the administration frequency, and meanwhile, improve the bioavailability of the drug. The effects of promoting skin wound healing and repairing are also achieved; a specific type of solubilizer is adopted, so that the medicine has good stability and is not easy to separate out; in addition, the pharmaceutical composition disclosed by the invention can be directly administrated through a wound and is convenient to use.

The application discloses a kind of cannabidiol heat-sensitive nano hydrogel preparation and its injection and its preparation method, the injection includes cannabidiol 5-15mg / mL, Poly (I:C) 0.5-1.5mg / mL and Pluronic F127 concentration is 20-30wt%.The injection can slow-release cannabidiol and Poly (I:C) and prolong its residence time at tumor site, reduce dosing frequency, effectively and continuously synergistic inhibition tumor, reduce side effects.

The present invention relates to the technical field of pharmaceutical preparation, and specifically discloses a brivaracetam sustained-release dry suspension and a preparation method thereof. The brivaracetam sustained-release dry suspension of the present invention is composed of a sustained-release drug-loaded resin, a suspending agent and a flavoring agent. The brivaracetam dry suspension prepared by the present invention through ion exchange resin drug loading and then sustained-release coating has a sustained-release effect, can reduce the daily dosing frequency, and can also overcome the problems of difficult administration of tablets, inconvenient carrying of oral solutions, and troublesome administration methods of injections.

The present invention relates to the field of peptide drugs, and particularly to a triple-target peptide and a derivative thereof. The triple-target peptide provided by the present invention exerts effects of lowering blood glucose, reducing blood lipids, and weight loss. Based on the above studies, the triple-target peptide provided by the present invention is further long-acting modified, and while retaining excellent effects for the specific indications described above, also has long-acting advantages, which can reduce dosing frequency, improve medication convenience, and enhance patient compliance. Experimental results show that the peptide and the long-acting derivative thereof provided by the present invention can significantly lower blood glucose, reduce blood lipids and / or induce weight loss, and can effectively prevent, treat, or ameliorate diabetes, obesity, obesity-related diseases, or metabolic disorders.

Provided is a transdermal drug delivery system comprising dronabinol. The dronabinol transdermal delivery system provides a drug plasma concentration at predetermined rate for a predetermined period of time, offering a simplified therapeutic regimen by decreasing dosing frequency for the treatment and / or prevention of nausea and / or vomiting associated with, for example, chemotherapy.

Provided is a transdermal drug delivery system comprising tetrahydrocannabinol (THC). Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decreasing dosing frequency for the treatment and / or prevention of pain and / or inflammation.

Provided is a transdermal drug delivery system comprising tetrahydrocannabinol (THC). Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decreasing dosing frequency for the treatment and / or prevention of pain and / or inflammation.

To provide a treatment option that provides an extended duration of therapeutic action while reducing dosing frequency in the treatment of diabetes.SOLUTION: Provided are compounds comprising a therapeutic polypeptide Fc conjugate having activity at one or more of the GIP, GLP-1, and glucagon receptors. These compounds provide activity at one or more of these receptors and have structural features that extend the duration of action. Also provided are methods for treating diseases and / or conditions such as obesity, chronic weight management, and type 2 diabetes.SELECTED DRAWING: None

The present invention relates to the field of therapy. More particularly, the present invention relates to therapeutic methods in which effector components are administered that require cellular uptake to become effective and / or exert their effect via intracellular (molecular) targets, such as but not limited to nucleic acid or oligonucleotide therapeutic agents. The present invention provides modes that extend the duration of the effect of the effector component and / or extend the interval of administration of the effector component and / or reduce the frequency of administration of the effector component and / or cause a (delayed) enhancement of the effect of the effector component.

The present application relates to tap water data processing technical field, disclose two stage gradual tap water dosing quantity optimization method based on deep learning, including steps: input sequence data of current time into model M1, output predicted dosing frequency of distribution pool of current time, and turbidity at the end of filter pool of next time; adjust the predicted dosing frequency of distribution pool of current time, obtain the actual dosing frequency of distribution pool of current time;Optimization model M2 is trained using database;After training, input sequence data of current time, artificially set distribution pool dosing frequency selection sequence into optimization model M2, output predicted turbidity at the end of filter pool of next time;With optimal turbidity at the end of filter pool as target, adjust the actual dosing frequency of distribution pool of current time.The present application solves the data set and hysteresis problem existing when implementing intelligent control, and can realize the optimization control of flocculation reagent dosing through successive adjustment on the basis of risk control.

Provided is a transdermal drug delivery system comprising dronabinol. The dronabinol transdermal delivery system provides a drug plasma concentration at predetermined rate for a predetermined period of time, offering a simplified therapeutic regimen by decreasing dosing frequency for the treatment and / or prevention of nausea and / or vomiting associated with, for example, chemotherapy.

The invention relates to the technical field of water treatment, and discloses a leachate Fenton treatment process based on a water pollution control agent, which comprises the following steps: adding a composite catalytic agent composed of an iron-based component and a copper graphite component into leachate, adding an oxidizing agent in a pulse mode, and monitoring an oxidation-reduction potential response curve, an instantaneous reaction factor is calculated according to the curve integral area, the dosing delay interval and the pump output frequency are adjusted according to the comparison result of the instantaneous reaction factor and a preset limit value, and the reaction circulating pump is controlled to generate fluid shear force within the delay interval to scour and strip a passivation layer on the surface of the agent. Physical synchronization of medicament injection and organic load degradation is realized, self-quenching of free radicals is inhibited, generation of chemical sludge is reduced, meanwhile, the alkalinity of the leachate is identified and compensated by utilizing potential signal characteristics, the stability of a catalytic environment is maintained, and the leachate treatment energy efficiency is improved.

This disclosure relates to aqueous suspension formulations of multi-target inhibitors. These formulations can be locally administered to target tissues such as eyes, prostate, that may be solved by the present disclosure are to (1) provide an injectable dosage form that allows direct delivery of a multi-target inhibitor to the proximity of the diseased tissue, (2) be compatible with the tissue of the site of administration, (3) form a drug reservoir at the administration site to allow prolonged supply of the drug to the diseased tissue, and thus reduce dosing frequency, (4) the release rate of the drug from the reservoir is such that above therapeutic level of the drug in the diseased tissue is achievable, (5) have physicochemical properties that are suitable for clinical uses, (6) be terminally sterilizable so that safety risk due to contamination of micro-organisms can be minimized, and (7) have a stability profile suitable for long term storage and distribution.

Relates to the field of chemical medicines, in particular to application of (-)-epigallocatechin gallate (EGCG) compounds. In particular to application of EGCG (epigallocatechin gallate) compounds in preparation of inhalation medicines for preventing and / or treating pulmonary fibrosis diseases, an inhalable medicine composition for preventing and / or treating the pulmonary fibrosis diseases and a method for preventing and / or treating the pulmonary fibrosis diseases. The EGCG compound is EGCG or a pharmaceutically acceptable salt, ester, hydrate or solvate thereof. The medicine / medicine composition taking the EGCG compound as the effective component, provided by the embodiment, can be used as an inhalable medicine for preventing and treating the pulmonary fibrosis, the administration dosage can be greatly reduced, a wider treatment window, lower adverse reaction and lower administration frequency are provided, and a new treatment choice is provided for patients with the pulmonary fibrosis.

The invention discloses a corrosion and scale inhibition and sterilization intelligent control system for a chemical circulating water system, and belongs to the technical field of chemical circulating water treatment. The system comprises an online water quality monitoring sensor, a circulating water flow sensor, a control unit, a variable-frequency dosing pump and a medicament storage unit which are arranged on a circulating water main pipeline, the online water quality monitoring sensor detects the pH value, hardness, conductivity and residual chlorine parameters of circulating water in real time, the control unit receives data of the sensor and analyzes the water quality trend through a built-in algorithm, the variable-frequency dosing pump is controlled to accurately add chemicals from the dosing tank, and meanwhile the dosing frequency is automatically adjusted according to the flow of the circulating water. And the dosing tank is provided with a liquid level sensor to monitor the residual amount of the medicament. The system realizes automatic monitoring of circulating water quality and accurate dosing, effectively maintains water quality stability, reduces medicament consumption, and guarantees safe and stable operation of the system.

Provided is a transdermal drug delivery system comprising dronabinol. The dronabinol transdermal delivery system provides a drug plasma concentration at predetermined rate for a predetermined period of time, offering a simplified therapeutic regimen by decreasing dosing frequency for the treatment and / or prevention of nausea and / or vomiting associated with, for example, chemotherapy.

The invention relates to the technical field of pharmaceutical preparations, and discloses a carergoline long-acting injection as well as a preparation method and application thereof. The injection comprises the following raw materials: sucrose acetate isobutyrate, absolute ethyl alcohol and medium chain triglyceride, wherein the mass ratio of the sucrose acetate isobutyrate to the absolute ethyl alcohol to the medium chain triglyceride is (68-72): (14-16): (14-16). The carergoline long-acting injection is in an in-situ gel dosage form, the optimal organic solvent and proportion are selected, the medicine directly enters blood circulation after being injected into the body, the first-pass effect is avoided, and the medicine utilization rate is increased; no stimulation is caused to gastrointestinal tracts, and adverse reactions are reduced; the long-acting release of the medicine is realized, the elimination half-life period is as long as 51.82 hours, the T max is 10 hours, the long-acting release mechanism reduces the administration frequency and the blood concentration fluctuation, and the effectiveness and the safety of the medicine can be improved.

The utility model relates to the technical field of injection production, in particular to an injection liquid preparation device which comprises a box body, a liquid level groove is formed in the surface of the box body, a liquid discharge pipe is installed on one side of the box body, a first motor is fixedly installed at the top of the box body, a liquid preparation assembly is arranged on the box body, and the liquid preparation assembly comprises a liquid preparation box. A second motor is fixedly mounted on one side of the liquid preparation box, a plurality of storage cylinders are fixedly connected to the top of the liquid preparation box, top covers are in threaded connection with the top ends of the storage cylinders, valves are mounted at the bottoms of the storage cylinders and on a liquid discharging pipe, and a first stirring roller is rotationally connected to the interior of the liquid preparation box; according to the scheme, by designing the liquid preparation assembly, during injection production, the dosing frequency of workers can be reduced, meanwhile, the injection can be subjected to secondary mixing and stirring, so that medicaments are fully fused, and the quality of the injection is effectively improved.